UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A Information

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.     )

Filed by Registrant		ü
Filed by Party other than Registrant
Check the appropriate box:
	Preliminary Proxy Statement							Confidential, for Use of the Commission
								Only (as permitted by Rule 14a-6(e)(2))
	Definitive Proxy Statement						ü	Definitive Additional Materials
	Soliciting Materials Pursuant to §240.14a-12

Pernix Therapeutics Holdings, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):
ü	No fee required.
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
	Fee paid previously with preliminary materials.
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing
	for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount previously paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:

---

PERNIX THERAPEUTICS HOLDINGS, INC.

33219 Forest West Street

Magnolia, Texas 77354

June 11, 2010

To Our Stockholders:

As you know, on March 9, 2010 we announced the consummation of the merger involving Golf Trust of America, Inc. (“GTA”) and Pernix Therapeutics, Inc. (“PTI”). As a result of the merger, PTI became our wholly-owned subsidiary and GTA changed its name to Pernix Therapeutics Holdings, Inc.

Our first post-merger Annual Meeting of Stockholders of the combined company is scheduled for July 22, 2010 at 9:00 a.m., local time, at the Chicago Marriott Downtown Magnificent Mile, 540 North Michigan Avenue, Chicago, Illinois 60611.

This year, we are taking advantage of the Securities and Exchange Commission’s Notice and Access proxy rule, which allows companies to furnish proxy materials via the Internet as an alternative to the traditional approach of mailing a printed set to each stockholder. We believe this approach provides you, as our stockholders, the proxy materials you need while reducing printing and postage costs associated with delivery and reducing the environmental impact of our Annual Meeting.

On this website, you will find our Proxy Statement for our 2010 Annual Meeting of Stockholders, our Form 10-K for GTA for the fiscal year ended December 31, 2009, and a Form 8-K announcing the closing of merger and which provides financial information for PTI as required under federal securities laws for the fiscal year ended December 31, 2009. Together, the Forms 10-K and 8-K constitute our Annual Report to Stockholders.

Thank you for your support of our company.

	Sincerely,
	Cooper C. Collins
	President and Chief Executive Officer